NOMAD POWER SOLUTIONS, INC. Cost of Revenue
NOMAD POWER SOLUTIONS, INC. (NMAD) reported Cost of Revenue of $356.00 thousand for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2023-11-09
- NOMAD POWER SOLUTIONS, INC. cost of revenue for the quarter ending 2023-09-30 was $356.00K, a 44.72% decline year-over-year.
- NOMAD POWER SOLUTIONS, INC. cost of revenue for the quarter ending 2023-06-30 was $522.56K, a 30.65% decline year-over-year.
- NOMAD POWER SOLUTIONS, INC. cost of revenue for the quarter ending 2023-03-31 was $519.48K, a 8.21% decline year-over-year.
- NOMAD POWER SOLUTIONS, INC. cost of revenue for the quarter ending 2022-09-30 was $643.96K.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month |
|---|---|---|---|
| 2023-09-30 | $356.00K 10-Q · filed 2023-11-09 | $878.56K derived: sum of 2 quarters · filed 2023-11-09 | $1.40M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $522.56K 10-Q · filed 2023-08-09 | $1.04M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $519.48K 10-Q · filed 2023-05-10 | ||
| 2022-09-30 | $643.96K 10-Q · filed 2023-11-09 | $1.40M derived: sum of 2 quarters · filed 2023-11-09 | $1.96M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $753.53K 10-Q · filed 2023-08-09 | $1.32M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $565.92K 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B |